MK
Therapeutic Areas
Liquidia Corporation Pipeline
| Drug | Indication | Phase |
|---|---|---|
| YUTREPIA™ (treprostinil) inhalation powder | Pulmonary Arterial Hypertension (PAH) | Approved (Tentative) |
| LIQ861 (treprostinil) inhalation powder | Pulmonary Arterial Hypertension (PAH) | Phase 3 |
| L606 (liposomal treprostinil) injection | Pulmonary Arterial Hypertension (PAH) and other rare pulmonary diseases | Pre-clinical |
Leadership Team at Liquidia Corporation
RA
Roger A. Jeffs, Ph.D.
Chief Executive Officer & Director
TS
Tushar Shah, M.D.
Chief Medical Officer
RJ
Robin J. Steele
Chief Commercial Officer
JA
Jason Adair
Chief Operating Officer
DL
David L. Tome
General Counsel & Corporate Secretary
RS
Rajiv Shukla
Chairman of the Board
PB
Paul B. Manning
Director
JP
John P. Hamill
Director
AM
Anne M. Phillips, M.D.
Director
KG
Kelley G. Downing
Director